Group 1 - The core viewpoint of the article highlights the recent stock performance of BGM, which saw a 5.58% increase, reaching $8.33 per share, with a total market capitalization of $1.532 billion as of August 21 [1] - Financial data indicates that as of March 31, 2025, BGM reported total revenue of $14.3114 million, reflecting a year-on-year growth of 13.92%, while the net profit attributable to shareholders was -$0.8612 million, a significant decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative sectors such as biopharmaceuticals, bio-extraction, and healthcare [1] Group 2 - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and the global livestock industry [1] - Tetracycline raw materials are used not only for producing human antibiotics but also support the safety of poultry and seafood in the global farming sector [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1]
博美集团上涨5.58%，报8.33美元/股，总市值15.32亿美元